Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Menopausal disorders (Venlafaxine - Menopausal disorders)

Records returned : 37 (on 16 Jul 2025 at 22:56:40). Return to search results for ' Menopausal disorders '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important

Off-label use.

 
Links :
Guidelines
Off Label
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Elleste Solo tablets - 1st line
 
Links :
Indication :
Status :
Green
Formulations :
  • Patches
Restrictions / Comments:

Important
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
 
Links :
Indication :
Status :
Green
Formulations :
  • Spray
Restrictions / Comments:

Important
Lenzetto spray. Caution with higher than licensed doses. Max supply of 20 containers per year to stay within licensed dose.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Gel
Restrictions / Comments:

Important
Oestrogel is the preferred gel option. Sandrena is an alternative option.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Femoston tablets - 1st line for women requiring sequential combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Femoston Conti - 1st line for women requiring continuous combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
Bijuve capsules - 1st line for women requiring continuous combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Prescribe generically
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Femseven Conti patches - less preferred. Only use in the event of product shortages.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Novofem tablets - Only use if there are product shortages with Elleste Duet
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important

Off-label use.

 
Links :
Guidelines
Off Label
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf

  • Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).
 
Links :
Guidelines
Off Label
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important

Off-label use.

 
Links :
Guidelines
Off Label
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important

Off-label use.

Off-label use

 
Links :
Guidelines
Off Label
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
Prescribe generically. Micronised progesterone oral capsules.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Pessaries
Restrictions / Comments:

Important

Progesterone pessaries have not been agreed for use as endometrial protection.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Recommend switching to a newer, lower risk formulation.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Guidelines
NFD1
Off Label
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
See narrative
Restrictions / Comments:

 
Links :